MPMarie Porte
Marie Porte
*This is an algorithmically generated author record based on publicly available information.
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Marie Porte has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Elvire Pons-Tostivint
Department of Medical Oncology, University Hospital of Nantes, Nantes, France
2 shared publications Jaafar Bennouna
2 shared publicationsJudith Raimbourg
2 shared publicationsPerrine Crequit
2 shared publicationsAdrien Vaudron
Nantes Université, CHU Nantes, Pôle Hospitalo-Universitaire 11: Santé Publique, Clinique des données, INSERM, Nantes, France
1 shared publicationAlice Boileve
Département de Médecine Oncologique, Gustave Roussy, Villejuif, France
1 shared publication
Latest Publications
- 19 June 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 244, 116900
Outcomes of patients treated by FGFR inhibitors according to alteration types: An agnostic monocentric retrospective cohort
- 19 June 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 244, 116900
Outcomes of patients treated by FGFR inhibitors according to alteration types: An agnostic monocentric retrospective cohort
- Open Access
- 9 July 2024
- Published by Elsevier in Lung Cancer
- Vol. 194
Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study
- 9 July 2024
- Published by Elsevier in Lung Cancer
- Vol. 194
Open AccessSecond-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study
- 23 November 2023
- Published by Elsevier in Clinical Lung Cancer
- Vol. 25 (2) , e101-e111.e2
A Multicenter Study Assessing the Real-World Use and Effectiveness of First-Line Chemotherapy Plus Immunotherapy in Advanced Small-Cell Lung Cancer (SCLC) Patients
- 23 November 2023
- Published by Elsevier in Clinical Lung Cancer
- Vol. 25 (2) , e101-e111.e2
A Multicenter Study Assessing the Real-World Use and Effectiveness of First-Line Chemotherapy Plus Immunotherapy in Advanced Small-Cell Lung Cancer (SCLC) Patients
- 25 September 2023
- Published by Elsevier in Bulletin du Cancer
- Vol. 110 (11) , 1094-1096
Durvalumab et tremelimumab en association à la chimiothérapie en première ligne du cancer bronchopulmonaire non à petites cellules (CBNPC) métastatique sans addiction oncogénique
- 25 September 2023
- Published by Elsevier in Bulletin du Cancer
- Vol. 110 (11) , 1094-1096
Durvalumab et tremelimumab en association à la chimiothérapie en première ligne du cancer bronchopulmonaire non à petites cellules (CBNPC) métastatique sans addiction oncogénique